U.S. Medical Equipment Stock News

NasdaqGS:TNYA
NasdaqGS:TNYABiotechs

Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts

Tenaya Therapeutics, Inc. recently reported a reduced net loss of US$19.27 million for the first quarter of 2026 and secured multiple scientific presentations, including new RIDGE-1 Phase 1b/2 data for its investigational TN-401 gene therapy in PKP2-associated arrhythmogenic right ventricular cardiomyopathy, now scheduled in the coming days at the ASGCT Annual Meeting 2026. These events, alongside company participation at Heart Failure 2026 and renewed analyst confidence, spotlight Tenaya’s...